What is antevel? Track your research field before the paper
Antevel is a research intelligence tool that overlays public upstream signals (funded grants, registered clinical trials, preprints, datasets) filtered to your niche, so you see where your field is going 12 to 18 months before publication.
Antevel is a research intelligence tool that shows you where your scientific field is heading before the paper is published. It overlays the public signals that appear upstream of publication, filters them to your niche, and turns them into a single dashboard with alerts.
If you have ever thought "by the time I read the paper, the work was done two years ago and everyone else read it at the same time," antevel is built for you.
The problem: publications are a lagging signal
When you rely on published papers to follow your field, you are always behind:
- A paper is the past. By the time it appears, the work was done one to two years earlier, and every reader receives it at the same moment.
- The upstream signals are public but scattered. Funded grants, registered trials, preprints, and deposited datasets all exist openly, spread across four or five separate databases that nobody monitors together.
- The tools that connect these flows are built for large organizations. The platforms that overlay grants, trials, and preprints together tend to be priced and sold for enterprise budgets, while the tools an individual can afford usually cover just one flow at a time.
The result: the "where is my field going" watch is done by hand, with Excel queries on NIH RePORTER, homemade preprint scripts, and manual ClinicalTrials.gov checks, or it is not done at all.
What antevel does
You define your niche once (for example "solid-tumor immunotherapy" or "AAV gene therapy"), and antevel builds a dashboard and alert stream from the early indicators of research activity in that niche.
| Signal | What it reveals |
|---|---|
| Funded grants (NIH RePORTER, CORDIS) | who just received money to work on it |
| Registered trials (ClinicalTrials.gov) | which programs are starting |
| Recent preprints (bioRxiv, medRxiv) | what is about to be published |
| New datasets (GEO, SRA, Zenodo) | which data was just generated |
These flows are linked through OpenAlex, the open scholarly graph, so every signal attaches to the same labs, funders, and topics. Instead of five tabs you get one connected view of your field forming in real time.
How it is different
- Upstream, not downstream. Most research tools focus on what has already been published. Antevel looks at the signal before the paper. It is the opposite vantage point.
- An operational tool, not a newsletter. You configure it and act on it continuously. A newsletter gets forwarded and forgotten; antevel is a watch you own.
- Affordable and individual. It delivers a multi-flow, niche-filtered overlay at a price an individual researcher or a small team can pay.
- 100% public data. No patient data, no scraping behind paywalls. Antevel warns you from real public signals; it does not predict or prophesy.
Who it is for
- Researchers (postdocs, young PIs, computational and translational scientists) planning career and grant strategy around where the field is going.
- Analysts and scouts (consultants, science journalists, biotech-focused VC analysts) who need an early read on a therapeutic area.
- Small biotech teams (competitive intelligence, business development, medical affairs) that need a trials, grants, and preprints watch without an enterprise price tag.
Why now
Public scientific APIs are finally mature and open (ClinicalTrials.gov v2, NIH RePORTER v2, bioRxiv, OpenAlex, Zenodo). At the same time, funding pressure in research makes "where is the money going" a question that matters more than ever. Antevel connects those open flows into the answer.
In one line
Antevel is the upstream watch on scientific research: the grants, trials, preprints, and datasets of your niche, connected and delivered before the paper. You are no longer up to date. You are ahead.